Beilu Pharmaceutical's Sees Strong Start to 2025 with Q1 Revenue and Profit Growth

Recently, Beilu Pharmaceutical (300016) released the "2025 First Quarter Report". Building on the stable growth in annual performance in 2024, Beilu Pharmaceutical has had a great start in 2025! In the first quarter of 2025, Beilu Pharmaceutical achieved operating income of 282.68 million yuan, a year-on-year increase of 36.23%; net profit attributable to shareholders of the listed company was 14.54 million yuan, a year-on-year increase of 26.13%; and net profit excluding non-recurring gains and losses attributable to shareholders of the listed company was 13.09 million yuan, a year-on-year increase of 14.34%.

During the reporting period, the performance growth of Beilu Pharmaceutical was driven by three core factors:

1. The chemical generic drug sector seized national procurement policy opportunities precisely, and the main products continuously expanded their market share in both the initial and subsequent bids, with sales steadily increasing, consolidating the profit foundation;

2. The traditional Chinese medicine sector achieved rapid integration and expansion through mergers and acquisitions, with the product pipeline and existing marketing network forming complementary advantages, becoming a new driver of performance growth;

3. Overseas market expansion results are evident as the construction of an international sales network has driven continuous quarterly growth in export business.

Beilu Pharmaceutical will continue to implement a dual strategy of "chemical drugs + Chinese medicine", while balancing both domestic and overseas markets. While focusing on steady business development, the company will simultaneously enhance profitability, providing strong support for high-quality development.